Table 1.
Comparison of Baseline versus 1-Week Variables of Interest Between All Participants and Pegloticase Responders
| Measurement | All Participants |
P valueb | Pegloticase Responders |
P valueb | ||
|---|---|---|---|---|---|---|
| Baseline, N = 9a | 1 week, N = 9a | Baseline, N = 7a | 1 week, N = 7a | |||
| Weight (kg) | 123 ± 35 | 122 ± 34 | 0.44 | 113 ± 28 | 113 ± 28 | 0.79 |
| Metabolic measures | ||||||
| Serum uric acid (mg/dL) | 6.4 (5.6, 7.6) | 0.5 (0.5, 4.6) | 0.01c | 6.4 (5.5, 7.8) | 0.5 (0.5, 0.5) | 0.02c |
| Fasting blood glucose (mg/dL) | 157 ± 71 | 144 ± 46f | 0.30 | 139 ± 44 | 152 ± 51d | >0.99 |
| Serum bilirubin (mg/dL) | 0.6 ± 0.2 | 0.9 ± 0.3 | 0.005 | 0.6 ± 0.2 | 1.0 ± 0.3 | 0.02 |
| Renal measures | ||||||
| Serum urea nitrogen | 13.2 ± 3.4 | 13.4 ± 4.9 | 0.86 | 12.7 ± 2.3 | 13.0 ± 3.2 | 0.85 |
| Serum creatinine (mg/dL) | 0.8 ± 0.2 | 0.7 ± 0.3 | 0.14 | 0.8 ± 0.2 | 0.7 ± 0.2 | 0.06 |
| Serum cystatin C (mg/L) | 0.9 ± 0.2g | 0.9 ± 0.1g | 0.79 | 0.8 ± 0.2 | 0.9 ± 0.1 | 0.73 |
| Urine uric acid (mg/dL) | 52.0 (34.0, 73.9) | 5.5 (2.8, 19.4) | 0.004c | 52.0 (37.8, 69.6) | 2.8 (2.8, 8.2) | 0.02c |
| Urine creatinine (mg/dL) | 135.8 ± 95.0 | 176.0 ± 157.7 | 0.17 | 144.0 ± 106.7 | 202.1 ± 170.2 | 0.12 |
| Urine microalbumin (μg) | 30.4 (7.7, 312.0) | 33.2 (13.5, 156.5)g | 0.11c | 21.9 (6.1, 171.2) | 22.1 (11.8, 90.0)e | 0.16c |
| Urine albumin-creatinine ratio (UACR) | 18 (9, 578) | 21 (6, 211)g | 0.84c | 15 (8, 298) | 10 (6, 38)e | 0.44c |
| Iohexol glomerular filtration rate (GFR) measures | ||||||
| Absolute GFR (mL/min) | 154 ± 22g | 172 ± 32 | 0.005 | 159 ± 18 | 169 ± 17 | 0.01 |
| GFR standardized body surface area (mL/min/1.73 m2) | 113 ± 20g | 122 ± 19 | 0.004 | 117 ± 17 | 125 ± 16 | 0.009 |
| 2D PC-MRI | ||||||
| Renal artery (mL/cycle) | 18.4 ± 5.0g | 18.2 ± 5.3g | 0.81 | 19.9 ± 4.9e | 20.1 ± 4.5e | 0.84 |
| Renal vein (mL/cycle)∗ | 18.3 ± 4.9g | 16.8 ± 3.6g | 0.32 | 19.5 ± 4.2e | 17.6 ± 3.0e | 0.31 |
| Cardiovascular measures | ||||||
| Systolic blood pressure (SBP) | 133 ± 10 | 132 ± 9 | 0.38 | 133 ± 12 | 130 ± 10 | 0.29 |
| Diastolic blood pressure (DBP) | 77 ± 9 | 85 ± 11 | 0.04 | 74 ± 7 | 82 ± 10 | 0.13 |
| Mean arterial pressure (MAP) | 96 ± 7 | 101 ± 10 | 0.06 | 94 ± 6 | 98 ± 9 | 0.19 |
| Cardiac MRI | ||||||
| End-diastolic volume (mL) | 136.2 ± 31.5f | 144.6 ± 24.6g | 0.02 | 145.1 ± 22.8e | 154.5 ± 16.9e | 0.06 |
| End systolic volume (mL) | 57.3 ± 12.8f | 60.8 ± 18.5g | 0.50 | 60.8 ± 9.7e | 66.1 ± 17.2e | 0.47 |
| Stroke volume (mL) | 79.0 ± 25.5f | 83.8 ± 14.6g | 0.45 | 84.4 ± 23.1e | 88.4 ± 13.7e | 0.67 |
| Ejection fraction | 57.3 ± 7.6f | 58.5 ± 7.7g | 0.75 | 57.5 ± 8.3e | 57.5 ± 8.3e | 0.99 |
| Cardiac output (L/min) | 6.4 ± 1.8f | 7.0 ± 0.9g | 0.41 | 6.7 ± 1.7e | 7.0 ± 1.1e | 0.64 |
| Peak radial strain (%) | 28.5 ± 3.1f | 27.3 ± 6.4f | 0.69 | 28.7 ± 3.3e | 26.1 ± 6.1e | 0.39 |
| Peak circumferential strain (%) | 17.2 ± 1.3f | 16.6 ± 2.5f | 0.58 | 17.3 ± 1.4e | 16.2 ± 2.5e | 0.35 |
| Peak longitudinal strain (%) | 15.6 ± 2.0f | 13.4 ± 2.2f | 0.02 | 15.4 ± 2.2e | 13.1 ± 2.2e | 0.03 |
| Aortic 4D flow MRI | ||||||
| Pulse wave velocity (m/s) | 4.8 ± 1.4f | 4.3 ± 0.8f | 0.31 | 4.4 ± 0.9e | 4.1 ± 0.5e | 0.56 |
| Mean wall shear stress (Pa) | 1.5 ± 0.2f | 1.4 ± 0.1f | 0.046 | 1.5 ± 0.2e | 1.4 ± 0.1e | 0.05 |
| Maximum wall shear stress (Pa) | 2.6 ± 0.3f | 2.5 ± 0.3f | 0.32 | 2.6 ± 0.4e | 2.6 ± 0.4e | 0.53 |
Note: In instances where sample sizes differ between baseline and 1 week, the reported P values are based on the smaller sample size, as incomplete pairs of data were excluded from the analyses. Bold values were considered statistically significant (P < 0.05).
a
Descriptive statistics are reported as mean ± SD or median (p25, p75).
b
Paired t-test.
c
Wilcoxon signed rank test with continuity correction; Wilcoxon signed rank exact test.
d
Data were collected from 5 participants.
e
Data were collected from 6 participants.
f
Data were collected from 7 participants.
g
Data were collected from 8 participants.